Journal of Clinical Endocrinology & Metabolism, Vol 79, 691-694, Copyright © 1994 by Endocrine Society

ARTICLES

Clinical review 61: Effects of growth hormone on human bone biology

SE Inzucchi and RJ Robbins
Neuroendocrinology Program, Yale University School of Medicine, New Haven, Connecticut 06520.

GH has considerable importance in the normal development and growth of bone. An additional role in the maintenance of the adult skeleton is suggested by the alterations in bone mineral density observed in states of deficient or excess GH secretion and in the bone formation response to GH replacement in GHD patients. Deficiency in the secretion of GH is also observed, with increasing and striking frequency after middle-age despite the lack of any defined pituitary disease or injury. Although a causal relationship between hyposomatotropism and osteopenia in normal elderly patients is hypothetical, intriguing therapeutic questions are raised. Preliminary trials of hGH in osteoporosis have not resulted in increases in BMD, but such studies suffer from methodological limitations, chief of which is the failure to account for the GH/IGF-I status of their subjects. Osteopenic patients with the lowest IGF-I levels may need to be assessed independently. The utility of hGH may be in preventing the senile component of osteoporosis, which appears to result mainly from defective bone formation. Such studies will require appropriate patient selection, longer treatment periods, and more sensitive measures of bone density. Combination and/or coherence therapy with other agents, particularly those that attenuate bone resorption, may also prove useful.

This article has been cited by other articles:

				M. Raschke, M. H. Rasmussen, S. Govender, D. Segal, M. Suntum, and J. S. Christiansen Effects of growth hormone in patients with tibial fracture: a randomised, double-blind, placebo-controlled clinical trial Eur. J. Endocrinol., March 1, 2007; 156(3): 341 - 351. [Abstract] [Full Text] [PDF]

				H. D. White, A. M. Ahmad, B. H. Durham, S. Chandran, A. Patwala, W. D. Fraser, and J. P. Vora Effect of Active Acromegaly and Its Treatment on Parathyroid Circadian Rhythmicity and Parathyroid Target-Organ Sensitivity J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 913 - 919. [Abstract] [Full Text] [PDF]

				P. Gillberg, H. Mallmin, M. Petren-Mallmin, S. Ljunghall, and A. G. Nilsson Two Years of Treatment with Recombinant Human Growth Hormone Increases Bone Mineral Density in Men with Idiopathic Osteoporosis J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4900 - 4906. [Abstract] [Full Text] [PDF]

				C. H. Gravholt, A. L. Lauridsen, K. Brixen, L. Mosekilde, L. Heickendorff, and J. S. Christiansen Marked Disproportionality in Bone Size and Mineral, and Distinct Abnormalities in Bone Markers and Calcitropic Hormones in Adult Turner Syndrome: A Cross-Sectional Study J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2798 - 2808. [Abstract] [Full Text] [PDF]

				R. G. Veldman, M. Frölich, S. M. Pincus, J. D. Veldhuis, and F. Roelfsema Apparently Complete Restoration of Normal Daily Adrenocorticotropin, Cortisol, Growth Hormone, and Prolactin Secretory Dynamics in Adults with Cushing's Disease after Clinically Successful Transsphenoidal Adenomectomy J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4039 - 4046. [Abstract] [Full Text]

				K. A. Woods, C. Camacho-Hübner, R. N. Bergman, D. Barter, A. J. L. Clark, and M. O. Savage Effects of Insulin-Like Growth Factor I (IGF-I) Therapy on Body Composition and Insulin Resistance in IGF-I Gene Deletion J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1407 - 1411. [Abstract] [Full Text]

				A. Colao, C. Di Somma, R. Pivonello, S. Loche, G. Aimaretti, G. Cerbone, A. Faggiano, G. Corneli, E. Ghigo, and G. Lombardi Bone Loss Is Correlated to the Severity of Growth Hormone Deficiency in Adult Patients with Hypopituitarism J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1919 - 1924. [Abstract] [Full Text]

				E. S. Kurland, F. K. W. Chan, C. J. Rosen, and J. P. Bilezikian Normal Growth Hormone Secretory Reserve in Men with Idiopathic Osteoporosis and Reduced Circulating Levels of Insulin-Like Growth Factor-I J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2576 - 2579. [Abstract] [Full Text]

				A. M. Boot, M. A. M. J. Engels, G. J. M. Boerma, E. P. Krenning, and S. M. P. F. de Muinck Keizer-Schrama Changes in Bone Mineral Density, Body Composition, and Lipid Metabolism during Growth Hormone (GH) Treatment in Children with GH Deficiency J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2423 - 2428. [Abstract] [Full Text] [PDF]